It's official: Pfizer, BioNTech ink enormous deal with Europe to provide 1.8B more COVID-19 vaccine doses RenBio joins bigwigs Eli Lilly, Regeneron in hunt for next gen COVID-19 antibodies after $24M financing What Amazon's potential move into at-home medical tests could mean for the market Emergent was unequipped to produce both J&J and AstraZeneca COVID-19 vaccines, execs tell lawmakers COVID-19 tracker: India's Bharat Biotech boosts vaccine production; Japan set to approve Moderna, AZ jabs HCA Healthcare CFO outlines M&A growth strategy, post-COVID hurdles facing the health system The Wheel deal: Virtual care startup rolls into $50M series B to grow telehealth software, clinician network CHS reports strong rebound in lower-acuity procedures compared to higher-acuity surgeries Featured Story | By Kevin Dunleavy A much-discussed COVID-19 vaccine supply deal between Pfizer, BioNTech and Europe is now official. The companies said they will supply 1.8 billion doses of the shot through 2023, bringing their total supply to the bloc at 2.4 billion. read more |
| |
|---|
|
Top Stories By Kyle LaHucik A year and a half ago, the disease targeted by RenBio's lead asset did not even exist in humans, but now the upstart biotech is emerging from stealth with a COVID-19 antibody hopeful and $24 million in financing to go up against Big Pharma in the battle for a variant-busting treatment. read more By Heather Landi Amazon is considering the launch of a new line of business that offers at-home medical tests, according to media reports. It's a potential move that wouldn't surprise many industry analysts. "Labs are a particularly good fit for the core strengths of Amazon," said consultant Nathan Ray. Here's how Amazon's next healthcare move could impact the market. read more By Fraiser Kansteiner Emergent BioSolutions execs said the "unprecedented" challenge of scaling up production for both AstraZeneca and Johnson & Johnson's COVID-19 vaccines caused its pandemic manufacturing struggles. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner India's Bharat Biotech said it will now be able to produce 200 million additional doses of its vaccine, known as Covaxin, per year. A key Japanese health panel endorsed the shots from AstraZeneca and Moderna, setting them up for full government approval as early as Friday. And more headlines. read more By Dave Muoio Growth is front of mind for the large for-profit system, particularly when it comes to in-market opportunities around continuing services. At the same time, CFO Bill Rutherford said HCA and others will likely feel the lingering impacts of disrupted utilization and workforce burnout for months to come. read more By Andrea Park With nearly $70 million in lifetime venture funding under its belt, Wheel isn’t looking to reinvent its eponymous device—just the entire telehealth industry. read more By Robert King Community Health System executives said lower-acuity services and procedures like diagnostics and screenings have seen a stronger rebound compared to more complex and higher-acuity surgeries. read more |
